Gemcitabine-mediated radiosensitization of human soft tissue sarcoma

Translational Oncology

Volumn 1, Issue 1, 2008, Pages 50-56

  Murphy, James D ^a,c   Lucas, David R ^b   Somnay, Yash R ^a   Hamstra, Daniel A ^a   Ray, Michael E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c American Society for Therapeutic Radiology and Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 59449091435     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.07121     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, and Thun MJ (2006). Cancer statistics, 2006. CA Cancer J Clin 56, 106-130.
2. Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, and Winchester D (1987). Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 205, 349-359.
3. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, and Brennan MF (1996). Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 14, 859-868.
4. Potter DA, Kinsella T, Glatstein E, Wesley R, White DE, Seipp CA, Chang AE, Lack EE, Costa J, and Rosenberg SA (1986). High-grade soft tissue sarcomas of the extremities. Cancer 58, 190-205.
5. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, et al. (1998). Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16, 197-203.
6. Catton CN, O'Sullivan B, Kotwall C, Cummings B, Hao Y, and Fornasier V (1994). Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys 29, 1005-1010.
7. Kilkenny JW III, Bland KI, and Copeland EM III (1996). Retroperitoneal sarcoma: the University of Florida experience. J Am Coll Surg 182, 329-339.
8. Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon F, and Nguyen Bui B (2001). Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer 92, 359-368.
9. Youssef E, Fontanesi J, Mott M, Kraut M, Lucas D, Mekhael H, and Ben-Josef E (2002). Long-term outcome of combined modality therapy in retroperitoneal and deep-trunk soft-tissue sarcoma: analysis of prognostic factors. Int J Radiat Oncol Biol Phys 54, 514-519.
10. Lawrence TS, Chang EY, Hahn TM, Hertel LW, and Shewach DS (1996). Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34, 867-872.
11. Lawrence TS, Davis MA, Hough A, and Rehemtulla A (2001). The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res 7, 314-319.
12. Lawrence TS, Eisbruch A, and Shewach DS (1997). Gemcitabine-mediated radiosensitization. Semin Oncol 24, S7-24-S7-28.
13. Shewach DS, Hahn TM, Chang E, Hertel LW, and Lawrence TS (1994). Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54, 3218-3223.
14. Huang P, Chubb S, Hertel LW, Grindey GB, and Plunkett W (1991). Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51, 6110-6117.
15. Ruiz van Haperen VW, Veerman G, Vermorken JB, and Peters GJ (1993). 2′,2′- Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 46, 762-766.
16. Ostruszka LJ and Shewach DS (2000). The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine. Cancer Res 60, 6080-6088.
17. McGinn CJ, Talamonti MS, Small W, Freedman GM, Berlin J, Kinsella TJ, Philip PA, Zalupski MM, Mulcahy MF, Meropol NJ, et al. (2004). A phase II trial of full-dose gemcitabine with concurrent radiation therapy in patients with resectable or unresectable non-metastatic pancreatic cancer [Abstract 96]. ASCO Program/Proceedings Gastrointestinal Cancers Symposium, January 22-24, 2004; San Francisco, California.
18. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, et al. (2001). Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19, 4202-4208.
19. Eisbruch A, Shewach DS, Bradford CR, Littles JF, Teknos TN, Chepeha DB, Marentette LJ, Terrell JE, Hogikyan ND, Dawson LA, et al. (2001). Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 19, 792-799.
20. Suh WW, Schott AF, Hayman JA, Schipper MJ, Shewach DS, and Pierce LJ (2004). A phase I dose escalation trial of gemcitabine with radiotherapy for breast cancer in the treatment of unresectable chest wall recurrences. Breast J 10, 204-210.
21. Fertil B, Dertinger H, Courdi A, and Malaise EP (1984). Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 99, 73-84.
22. Hoy CA, Seamer LC, and Schimke RT (1989). Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/ DNA histogram. Cytometry 10, 718-725.
23. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, DeMoss EV, Seipp C, Sindelar WF, Sugarbaker P, et al. (1982). The treatment of softtissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 196, 305-315.
24. Hartmann JT, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, and Bokemeyer C (2006). An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 24, 249-253.
25. Look KY, Sandler A, Blessing JA, Lucci JA III, and Rose PG (2004). Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 92, 644-647.
26. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, et al. (2007). Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25, 2755-2763.
27. Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, et al. (2000). Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 45, 177-181.
28. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, and Galanis E (2002). Phase II trial of gemcitabine in advanced sarcomas. Cancer 94, 3225-3229.
29. Okuno S, Ryan LM, Edmonson JH, Priebat DA, and Blum RH (2003). Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 97, 1969-1973.
30. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, and Benjamin RS (2001). Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19, 3483-3489.
31. Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, and Possinger K (2000). Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 11, 325-329.
32. Svancarova L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, Keizer HJ, Hermans C, van Glabbeke M, Verweij J, et al. (2002). Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38, 556-559.
33. Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, and Karen A (2006). Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol 29, 59-61.
34. Kent E, Sandler H, Montie J, Lee C, Herman J, Esper P, Fardig J, and Smith DC (2004). Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol 22, 2540-2545.
35. Bruso CE, Shewach DS, and Lawrence TS (1990). Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 19, 1411-1417.
36. Iliakis G, Kurtzman S, Pantelias G, and Okayasu R (1989). Mechanism of radiosensitization by halogenated pyrimidines: effect of BrdU on radiation induction of DNA and chromosome damage and its correlation with cell killing. Radiat Res 119, 286-304.
37. Gregoire V, Beauduin M, Bruniaux M, De Coster B, Octave Prignot M, and Scalliet P (1998). Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int J Radiat Biol 73, 511-520.
38. Lawrence TS, Chang EY, Hahn TM, and Shewach DS (1997). Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′- difluoro-2′-deoxycytidine (gemcitabine). Clin Cancer Res 3, 777-782.
39. Chen M, Hough AM, and Lawrence TS (2000). The role of p53 in gemcitabine- mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol 45, 369-374.
40. Pauwels B, Korst AE, Andriessen V, Baay MF, Pattyn GG, Lambrechts HA, Pooter CM, Lardon F, and Vermorken JB (2005). Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53. Radiat Res 164, 642-650.
41. Baker CH, Banzon J, Bollinger JM, Stubbe J, Samano V, Robins MJ, Lippert B, Jarvi E, and Resvick R (1991). 2′-Deoxy-2′-methylenecytidine and 2′-deoxy- 2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34, 1879-1884.
42. Flanagan SA, Robinson BW, Krokosky CM, and Shewach DS (2007). Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers. Mol Cancer Ther 6, 1858-1868.
43. Robinson BW, Im MM, Ljungman M, Praz F, and Shewach DS (2003). Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res 63, 6935-6941.
44. Pisters PW, Ballo MT, Bekele PF, Feig P, Lin JN, Cormier RS, and Benjamin SR (2004). Phase I trial using toxicity severity weights for dose finding of gemcitabine combined with radiation therapy and subsequent surgery for patients with extremity and trunk soft tissue sarcomas. J Clin Oncol 22(14S), 9008.
45. Feng M, Murphy JD, Griffith KA, Baker LH, Sondak VK, Lucas DR, McGinn CJ, and Ray ME (2007). Long-term outcomes after radiation therapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys 69, 103-110.
46. Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, et al. (2001). Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 28, 25-33.
47. Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, and Ben-Josef E (2007). Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68, 801-808.